Skip to main content
. 2015 Nov 23;7(Suppl 1):13–31. doi: 10.4137/TOG.S30534

Table 3.

An overview of cancer patients’ clinical outcome after treatment with c-MET inhibitors within clinical studies.

TUMOR TYPE PHASE DRUG RESPONSE RATE PFS OS REF.
NSCLC III Tivantinib + erlotinib vs. placebo + erlotinib 8.4% vs. 6.5% 2.9 mo vs. 2 mo 12.9 mo vs. 11.2 mo 68
NSCLC III Onartuzumab + erlotinib vs. placebo + erlotinib NA 2.6 mo vs. 2.7 mo 6.8 mo vs. 9.1 mo 65
NSCLC III Crizotinib vs. CT (pemetrexed or docetaxel) 65% vs. 20% 7.7 mo vs. 3 mo 20.3 mo vs. 22.8 mo 90
NSCLC III Crizotinib vs. CT (pemetrexed + cisplatin or carboplatin) 74 vs. 45% 10.9 mo vs. 7 mo NA 94
NSCLC II Erlotinib vs. cabozantinib vs. erlotinib + cabozantinib NA 1.9 mo vs. 3.9 mo vs. 4.1 mo 4.0 mo vs. na vs. na 96
NSCLC II Ficlatuzumab + geftinib vs. geftinib 43% vs. 40% 5.6 mo vs. 4.7 mo NA 170
RCC II Foretinib 13.5% 9.3 mo NA 106
RCC II Rilotumumab 10 mg vs. 20 mg 2.5% vs. 0% 3.7 mo vs. 2.0 mo 14.9 mo vs. 17.6 mo 171
RCC I Cabozantinib PR 28%, SD 52% 12.9 mo 15 mo 172
RCC III Cabozantinib + rosiglitazone 28% 14.7 mo NA 173
Solid tumors (mainly RCC and colorectal cancer) I Savolitinib 3 RCC pts achieved PR, 1 pt CRC achieved PR NA NA 72
Prostate cancer III Cabozantinib vs. prednisone 41% vs. 3% 5.5 mo vs. 2.8 mo 11 mo vs. 9.8 mo 174
Prostate cancer II Mitoxantrone + prednisone + rilotumumab vs. mitoxantrone + prednisone + placebo 11% vs. 14% 3.0 mo vs. 2.9 mo 12.2 mo vs. 11.1 mo 175
Colorectal cancer I/II Cetuximab + irinotecan + tivantinib vs. cetuximab + irinotecan + placebo 45% vs. 33% 8.3 mo vs. 7.3 mo NA 176
Colorectal cancer I/II Panitumumab + rilotumumab vs. panitumumab + ganitumumab vs. panitumumab + placebo 31% vs. 22% vs. 21% 5.2 mo vs. 5.3 mo vs. 3.7 mo NA 177
Esophagogastric cancer II Epirubicin + cisplatin + xeloda + rilotumumab vs. epirubicin + cisplatin + xeloda + placebo 38% vs. 24% 5.6 mo vs. 4.2 mo 11.1 mo vs. 8.9 mo 178
Gatric cancer II Forentinib (intermittent vs. daily cohort) 0% vs. 0% 1.7 mo vs. 1.8 mo 7.4 mo vs. 4.3 mo 179
Hepatocellular cancer II Tivantinib vs. placebo 1% vs. 0% 1.5 mo vs. 1.4 mo 6.6 vs. 6.2 mo 153
Hepatocellular cancer II Cabozantinib 5% 4.4 mo 15.1 mo 180
Hepatocellular cancer I/II Foretinib 24% 4.2 mo NA 181
Uveal melanoma II Cabozantinib NA 4.8 mo 12.6 mo 182
Melanoma II Cabozantinib PR 5%, SD 57% 4.2 mo NA 183
Breast cancer II Cabozantinib PR 14%, SD 57% 4.3 mo NA 184
HNSCC II Foretinib NA 3.65 mo 5.59 mo 185
Germ cell tumors II Tivantinib PR 0%, SD 20% 1.0 mo 6.0 mo 186
Glioblastoma II Rilotumumab (10 vs. 20 mg/kg) 0% vs. 0% 4.1 mo vs. 4.3 mo 6.5 mo vs. 5.4 mo 144
Sarcoma II Crizotinib PR 0%, SD 58.3%, PD 41.7% 5.25 mo NA 187
Thyroid cancer III Cabozantinib vs. placebo 28% vs. 0% 11.2 mo vs. 4.0 mo NA 188

Abbreviations: HNSCC, head and neck squamous cell carcinoma; mo, months; NA, not available; NSCLC, non small cell lung cancer; OS, overall survival; PFS, progression free survival; PR, partial response; RCC, renal cancer carcinoma; SD, stable disease.